Constitutive activation of JAK2 signaling in JAK2, CALR, and MPL mutant settings as well as in triple-negative MPN has provided a rational basis to develop JAK2 inhibition as a therapeutic approach in MPN [34]. The gene discussed is MPL; the disease is myeloproliferative disorder.